Bo Li
Author directoryOther people with similar names: Bo Li (Tsinghua, Baidu), Bo Li, Bo Li, Bo Li (Chinese Academy of Sciences), Bo Li, Bo Li, Bo Li, Bo Li (Xi'an Jiaotong University), Bo Li (Hebei), Bo Li, Bo Li, Bo Li (BeiHang), Bo Li (Chinese Academy of Sciences), Bo Li (NUS, Google), Bo Li (Vanderbilt, UIUC)
Unverified author pages with similar names: Bo Li
2026
DrugClaw and DrugAudit: A Primary-Source-Grounded Agent and Authority-Aware Benchmark for Drug-Information Question Answering
Qing Wang | Bo Li | Jialu Liang | Daling Shi | Bob Zhang | Qianqian Song
Findings of the Association for Computational Linguistics: EMNLP 2026
Qing Wang | Bo Li | Jialu Liang | Daling Shi | Bob Zhang | Qianqian Song
Findings of the Association for Computational Linguistics: EMNLP 2026
Drug-information question answering is a high-stakes setting where hallucinated facts can mislead clinical decision-making and the provenance of each cited fact matters as much as the fact itself. We present DrugClaw, a multi-agent retrieval-augmented system that queries a registry of drug and pharmacovigilance skills via a reflection-driven state-machine workflow and returns answers grounded in primary regulatory or peer-reviewed records. We also contribute DrugAudit, a 3,772-item authority-aware benchmark with an evaluation panel that scores upstream-of-gold source match, token-level semantic snippet overlap, and citation faithfulness under a dual-judge LLM-as-judge protocol with inter-judge κ = 0.88 (almost-perfect). Across DrugAudit plus drug-related subsets of MedQA (751) and PubMedQA (512), DrugClaw is top-1 on every column of the headline table: composite Evidence Index under both judges, judge-mediated answer correctness, primary-source rate (0.918, +10.1 pp over next-best), faithfulness (0.887, +5.9 pp), MedQA (0.920), and PubMedQA (0.693).